<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34611034</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1708-8267</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of investigative medicine : the official publication of the American Federation for Clinical Research</Title><ISOAbbreviation>J Investig Med</ISOAbbreviation></Journal><ArticleTitle>Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines.</ArticleTitle><Pagination><StartPage>61</StartPage><EndPage>67</EndPage><MedlinePgn>61-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jim-2021-002051</ELocationID><Abstract><AbstractText>Long COVID is characterized by the emergence of multiple debilitating symptoms following SARS-CoV-2 infection. Its etiology is unclear and it often follows a mild acute illness. Anecdotal reports of gradual clinical responses to histamine receptor antagonists (HRAs) suggest a histamine-dependent mechanism that is distinct from anaphylaxis, possibly mediated by T cells, which are also regulated by histamine. T cell perturbations have been previously reported in post-viral syndromes, but the T cell landscape in patients who have recovered from mild COVID-19 and its relationship to both long COVID symptoms and any symptomatic response to HRA remain underexplored. We addressed these questions in an observational study of 65 individuals who had recovered from mild COVID-19. Participants were surveyed between 87 and 408 days after the onset of acute symptoms; none had required hospitalization, 16 had recovered uneventfully, and 49 had developed long COVID. Symptoms were quantified using a structured questionnaire and T cell subsets enumerated in a standard diagnostic assay. Patients with long-COVID had reduced CD4+ and CD8+ effector memory (EM) cell numbers and increased PD-1 (programmed cell death protein 1) expression on central memory (CM) cells, whereas the asymptomatic participants had reduced CD8+ EM cells only and increased CD28 expression on CM cells. 72% of patients with long COVID who received HRA reported clinical improvement, although T cell profiling did not clearly distinguish those who responded to HRA. This study demonstrates that T cell perturbations persist for several months after mild COVID-19 and are associated with long COVID symptoms.</AbstractText><CopyrightInformation>&#xa9; American Federation for Medical Research 2022. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glynne</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Physicians Clinic, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahmasebi</LastName><ForeName>Natasha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>King's College London School of Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gant</LastName><ForeName>Vanya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Departments of Infection and Microbiology, University College London Hospitals NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Rajeev</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9573-0505</Identifier><AffiliationInfo><Affiliation>Stem Cell Laboratory, UCL Cancer Institute, London, UK rajeev.gupta@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manual Blood Sciences, Health Services Laboratories, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Investig Med</MedlineTA><NlmUniqueID>9501229</NlmUniqueID><ISSNLinking>1081-5589</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006633">Histamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>820484N8I3</RegistryNumber><NameOfSubstance UI="D006632">Histamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006632" MajorTopicYN="N">Histamine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006633" MajorTopicYN="N">Histamine Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016176" MajorTopicYN="N">T-Lymphocyte Subsets</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="Y">T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">diagnostic tests</Keyword><Keyword MajorTopicYN="N">immunologic tests</Keyword><Keyword MajorTopicYN="N">routine</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>6</Day><Hour>5</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34611034</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pii">jim-2021-002051</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. . Post-Acute COVID-19 syndrome. Nat Med 2021;27:601&#x2013;15. 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, et al. . Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur 2021;6:100122. 10.1016/j.lanepe.2021.100122</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs A, Vassall A. Sci virus dialysis 1, 2020.</Citation></Reference><Reference><Citation>Gorna R, MacDermott N, Rayner C, et al. . Long COVID guidelines need to reflect lived experience. Lancet 2021;397:455&#x2013;7. 10.1016/S0140-6736(20)32705-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32705-7</ArticleId><ArticleId IdType="pmc">PMC7755576</ArticleId><ArticleId IdType="pubmed">33357467</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenu EW, van Driel ML, Staines DR, et al. . Immunological abnormalities as potential biomarkers in chronic fatigue Syndrome/Myalgic encephalomyelitis. J Transl Med 2011;9:81. 10.1186/1479-5876-9-81</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-9-81</ArticleId><ArticleId IdType="pmc">PMC3120691</ArticleId><ArticleId IdType="pubmed">21619669</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandarano AH, Maya J, Giloteaux L, et al. . Myalgic Encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations. J Clin Invest 2020;130:1491&#x2013;505. 10.1172/JCI132185</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI132185</ArticleId><ArticleId IdType="pmc">PMC7269566</ArticleId><ArticleId IdType="pubmed">31830003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. . Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 2020;183:158&#x2013;68. 10.1016/j.cell.2020.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev Immunol 2020;20:529&#x2013;36. 10.1038/s41577-020-0402-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0402-6</ArticleId><ArticleId IdType="pmc">PMC7389156</ArticleId><ArticleId IdType="pubmed">32728222</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, Mentzer AJ, Liu G, et al. . Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol 2020;21:1336&#x2013;45. 10.1038/s41590-020-0782-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0782-6</ArticleId><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM, Mateus J, Kato Y, et al. . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021;371. 10.1126/science.abf4063. [Epub ahead of print: 05 Feb 2021].</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty SE, Guo Y, Heath K, et al. . Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ 2021;373:n1098. 10.1136/bmj.n1098</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1098</ArticleId><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R, Gant VA, Williams B, et al. . Increased complement receptor-3 levels in monocytes and granulocytes distinguish COVID-19 patients with pneumonia from those with mild symptoms. Int J Infect Dis 2020;99:381&#x2013;5. 10.1016/j.ijid.2020.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7836814</ArticleId><ArticleId IdType="pubmed">32771640</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A'Court C, et al. . Management of post-acute covid-19 in primary care. BMJ 2020;370:m3026. 10.1136/bmj.m3026</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Keswani A, Dhana K, Rosenthal JA, et al. . Atopy is predictive of a decreased need for hospitalization for coronavirus disease 2019. Ann Allergy Asthma Immunol 2020;125:479&#x2013;81. 10.1016/j.anai.2020.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anai.2020.07.012</ArticleId><ArticleId IdType="pmc">PMC7368420</ArticleId><ArticleId IdType="pubmed">32693208</ArticleId></ArticleIdList></Reference><Reference><Citation>Larbi A, Fulop T. From &#x201c;truly na&#xef;ve&#x201d; to &#x201c;exhausted senescent&#x201d; T cells: When markers predict functionality. Cytometry Part A 2014;85:25&#x2013;35. 10.1002/cyto.a.22351</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.22351</ArticleId><ArticleId IdType="pubmed">24124072</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachs B, Hertl M, Merk HF. Histamine receptors on lymphocytes: distribution and functional significance. Skin Pharmacol Appl Skin Physiol 2000;13:313&#x2013;23. 10.1159/000029939</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000029939</ArticleId><ArticleId IdType="pubmed">11096373</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond RA, Lucero Garcia-Rojas EY, Hegde A, et al. . Therapeutic potential of targeting &#xdf;-Arrestin. Front Pharmacol 2019;10:124. 10.3389/fphar.2019.00124</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00124</ArticleId><ArticleId IdType="pmc">PMC6414794</ArticleId><ArticleId IdType="pubmed">30894814</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso N, Zappia CD, Cabrera M, et al. . Physiological implications of biased signaling at histamine H2 receptors. Front Pharmacol 2015;6:45. 10.3389/fphar.2015.00045</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2015.00045</ArticleId><ArticleId IdType="pmc">PMC4354273</ArticleId><ArticleId IdType="pubmed">25805997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruzieh M, Batizy L, Dasa O, et al. . The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review. Scand Cardiovasc J 2017;51:243&#x2013;7. 10.1080/14017431.2017.1355068</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14017431.2017.1355068</ArticleId><ArticleId IdType="pubmed">28738696</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, et al. . Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun 2021;4:100100. 10.1016/j.jtauto.2021.100100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Laing AG, Lorenc A, Del Molino Del Barrio I, et al. . Author correction: a dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med 2020;26:1663. 10.1038/s41591-020-1079-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1079-x</ArticleId><ArticleId IdType="pmc">PMC7479399</ArticleId><ArticleId IdType="pubmed">32908251</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu W-C, et al. . Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020;181:1036&#x2013;45. 10.1016/j.cell.2020.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett F, Luxenberg D, Ling V, et al. . Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol 2003;170:711&#x2013;8. 10.4049/jimmunol.170.2.711</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.2.711</ArticleId><ArticleId IdType="pubmed">12517932</ArticleId></ArticleIdList></Reference><Reference><Citation>Jubel JM, Barbati ZR, Burger C, et al. . The role of PD-1 in acute and chronic infection. Front Immunol 2020;11:487. 10.3389/fimmu.2020.00487</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00487</ArticleId><ArticleId IdType="pmc">PMC7105608</ArticleId><ArticleId IdType="pubmed">32265932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Richards A, Barrasa MI, et al. . Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proc Natl Acad Sci U S A 2021;118. 10.1073/pnas.2105968118. [Epub ahead of print: 25 May 2021].</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2105968118</ArticleId><ArticleId IdType="pmc">PMC8166107</ArticleId><ArticleId IdType="pubmed">33958444</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>